News Content
The original manufacturer of Cialis is Eli Lilly and Company, a well-known American multinational pharmaceutical company. The company is headquartered in Indianapolis, Indiana, USA, with a history of more than 140 years of pharmaceutical research and development, and is one of the world's well-known prescription drug manufacturers. Cialis was developed by Eli Lilly and another biotechnology company, ICOS Corporation, and was first approved for marketing by the US Food and Drug Administration (FDA) in 2003.
Compared with similar drugs such as Viagra, the biggest advantage of Cialis is its duration. The main active ingredient of Cialis is Tadalafil, which can last up to 36 hours, so it is nicknamed the "weekend pill", which provides patients with greater flexibility and improved quality of life.
In addition to domestic production in the United States, Eli Lilly has multiple manufacturing bases and cooperative factories around the world, covering the European, Asian and Latin American markets to ensure the stability of Cialis' supply chain in different countries and regions. With the extensive layout of Cialis in the global market, Eli Lilly has gradually established a complete set of mature international marketing systems.
However, Cialis's road to the global market is not smooth sailing. In 2017, the patent period of Cialis in the United States officially expired, which marked the beginning of generic drug manufacturers in many countries around the world. Generic drug powers represented by India, such as Cipla, Sun Pharma, Aurobindo and other pharmaceutical companies, have successively launched lower-priced tadalafil generic drugs, greatly changing the market landscape.
In the Chinese market, Cialis was officially introduced by Eli Lilly in 2004, becoming the second legally marketed ED drug in China after Viagra. In order to better adapt to the Chinese market, Eli Lilly has also adopted a localization strategy, established cooperation with domestic companies, and promoted Cialis through multi-channel e-commerce platforms. At the same time, the China National Medical Products Administration (NMPA) has also approved a number of domestic Tadalafil generic drugs for listing in recent years, which has further intensified the competition between original drugs and generic drugs.
Despite this, Cialis, as an original brand, still maintains a high brand awareness and user loyalty. Eli Lilly has strict standards for maintaining drug quality control, and continues to conduct clinical research to continuously expand the potential use of Cialis in other fields, such as the treatment of diseases such as pulmonary arterial hypertension.
From a global strategic perspective, Eli Lilly has not stopped at the sales of the original drug, but actively promoted the improved dosage form and combination therapy of Cialis before and after the patent expires. For example, some studies are exploring the combination of tadalafil with other ingredients to maximize the therapeutic effect. In addition, Eli Lilly is also actively developing digital healthcare, using artificial intelligence and remote diagnosis and treatment to provide patients with personalized medication recommendations and health management services.
In summary, Eli Lilly, the manufacturer of Cialis, is not only the creator of this drug, but also one of the promoters of global medical innovation. With the intensification of the global aging trend and the increase in people's attention to sexual health, Cialis and its generic drugs are expected to continue to maintain market vitality in the next decade. How Eli Lilly can maintain its leading position as an original brand in the fierce market competition will also become the focus of the industry's continued attention.
